In an ambitious stride towards transforming the landscape of neurological drug development, a consortium comprising Chromos Labs, Tessara Therapeutics, Quantum Brilliance, Axol Biosciences, and the University of Melbourne has announced plans to create a quantum-enabled brain-on-chip platform. This innovative platform aims to provide real-time insights into human neural activity by utilizing advanced 3D human neural micro-tissues.
Addressing Challenges in Neurological Drug Development
The field of neurological drug development is fraught with challenges, primarily due to the limitations of current preclinical models that often fail to predict human outcomes accurately. The consortium’s initiative seeks to mitigate these risks by capturing functional neural activity within human-relevant 3D tissue models. By doing so, researchers will be able to evaluate disease effects and treatment responses more effectively, thus enhancing decision-making throughout the drug development pipeline.
A New Standard in Drug Discovery
Dr. Christos Papadimitriou, Co-Founder and CEO of Tessara Therapeutics, emphasized the significance of this collaboration in establishing a new standard for neurological drug discovery. The platform aligns with an evolving global regulatory landscape that increasingly favors human-relevant methods for identifying and advancing novel therapies. By harnessing the combined expertise of its partners, the consortium aims to expedite the creation of improved treatments for individuals affected by neurological diseases.
Innovative Fabrication Techniques
The consortium has already made significant headway, having successfully integrated diamond micropillar arrays with Tessara’s RealBrain® micro-tissues. This accomplishment marks a world-first in high-aspect-ratio pillar fabrication, demonstrating the capability to detect millivolt-scale electrical signals that are critical to understanding neural activity. Dr. Nikolai Dontschuk, Founder and CEO of Chromos Labs, noted that the initial phase of the project focused on pioneering fabrication techniques that allow for in-depth analysis of neural tissues.
Expanding the Scope of Research
The next phase of this project will involve expanding the field of view to accurately measure electrical signals across the entire RealBrain micro-tissues. This comprehensive approach will ensure that the consortium captures a holistic representation of the neural network state. Associate Professor David Simpson from the University of Melbourne remarked on the importance of this stage for translating research into practical applications in Australia, emphasizing the collaboration between technology developers and end-users.
Diverse Expertise Driving the Initiative
Each partner in the consortium plays a vital role in the platform’s development. Chromos Labs contributes its expertise in diamond nano-pillar sensing chip technology, while Tessara provides the RealBrain® human neural micro-tissue platform. Quantum Brilliance is tasked with scaling the manufacturing of sensor chips, and Axol Biosciences supplies high-quality human iPSC-derived neurons, ensuring standardized biological inputs. This collaborative effort exemplifies a blend of advanced technology and manufacturing capabilities that can drive innovation in the biotech sector.
The Importance of Scalable Quantum Technology
Dr. Marcus Doherty, Co-Founder and Chief Technology Officer of Quantum Brilliance, highlighted the necessity of accessible, scalable quantum-grade diamond for realizing the project’s ambitions. Establishing a viable manufacturing pathway for diamond-based products will not only enhance the consortium’s capabilities but also unlock significant social and economic potential, both in Australia and globally.
Government Support for Groundbreaking Research
The consortium’s groundbreaking project has garnered financial support from the Australian Government through its Critical Technologies Challenge Program. This funding underscores the significance of the initiative and its potential to reshape how neurological diseases are studied and treated.
Future Implications for Drug Discovery
As the consortium moves forward, the implications of this quantum-enabled brain-on-chip platform extend beyond immediate research applications. By providing a more accurate and human-relevant framework for drug discovery, the platform could potentially lead to faster and more efficient pathways for developing new therapies for neurological conditions such as Alzheimer’s, epilepsy, and schizophrenia.
- Key Takeaways:
- A consortium has formed to develop a quantum-enabled brain-on-chip platform for neurological drug discovery.
- The initiative aims to improve the predictability of preclinical models by utilizing human-relevant 3D neural micro-tissues.
- Each partner contributes specialized technology, fostering a collaborative approach to innovation in biotech.
- The project is supported by the Australian Government, indicating its importance in advancing critical technologies.
In conclusion, the consortium’s work represents a significant leap forward in the quest to enhance neurological drug development. By integrating cutting-edge quantum technology with human-relevant tissue models, this initiative not only holds the promise of more effective treatments but also sets a precedent for future research in the field. As the project unfolds, it has the potential to revolutionize how we approach the understanding and treatment of complex neurological disorders.
Read more → www.indystar.com